STAT August 3, 2022
The lack of diversity in clinical trials unfairly skews American medicine and costs billions of dollars a year in early deaths and poor health. Proven economic incentives to recruit more diverse participants can dramatically change the picture — if the will exists to employ them.
The scope of the problem was laid out in a new report that Congress requested from the National Academies of Sciences, Engineering, and Medicine, which we as committee members helped write.
Each year, government and industry test the safety and efficacy of new pharmaceutical agents and devices before they are allowed on the market. In drug trials, one group of participants typically receives the drug and another gets a placebo or the standard of care...
Today's Sponsors
Today's Sponsor